The Microbiological Profile of Diabetic Foot Infections
Background: Diabetic foot infections are a common cause of morbidity and mortality. This study was conducted in diabetic patients with foot ulcers to determine the bacterial profile and their anti-microbial pattern. Of the 68 patients, 44 were males and 24 were females. The presence of diabetic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2012-05-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/1991/4064_E(C)_F(P)_PF(V)_PFA(A)_P(_)[2].pdf |
| Summary: | Background: Diabetic foot infections are a common cause of
morbidity and mortality. This study was conducted in diabetic
patients with foot ulcers to determine the bacterial profile and
their anti-microbial pattern. Of the 68 patients, 44 were males
and 24 were females. The presence of diabetic neuropathy was
observed in 43(63.2%) patients. The swabs from 56 patients
showed a positive culture and 12 patients did not grow any
organisms. A total of 92 organisms were isolated from 56 patients
with growth. 12(17.6%) patients had polymicrobial infections.
S.aureus (26.1%) was the predominant pathogen which was
isolated, followed by E.coli (18.4%).
Methods: This study was conducted on clinical specimens
which were taken from 68 patients with diabetic foot infections,
over a 1 year period. The clinical specimens were processed by
using the standard aerobic microbiological techniques. The antimicrobial susceptibility pattern was studied by the Kirby-Bauer
disc diffusion method.
Result: S.aureus was the most common isolate which was
recovered from 26.1% of the cases. Other organisms which
were isolated were E.coli (18.4%),,Klebsiella (9.7%), Proteus spp
(6.5%), NFGNB(14.1%),,Pseudomonas aeruginosa (13%) and
Enterococcus spp (4.3%).
Conclusion: The anti-microbial susceptibility data from our
study suggests that piperacillin/tazobactum or cefeperazone /
sulbactum would be appropriate for antibiotic coverage. |
|---|---|
| ISSN: | 2249-782X 0973-709X |